Korea Seeks To Sharpen Clinical Trial Edge Amid Growing Competition
This article was originally published in PharmAsia News
South Korea has unveiled steps to buoy the global competitiveness of its clinical trial sector to meet a goal of becoming one of the world's top players in the field by 2020. The health ministry is planning to form an integrated information system and new network, invite more global clinical trials into the country and nurture the CRO industry, among other measures.
You may also be interested in...
After completing a major financing last year, expectations are rising at D&D Pharmatech as it progresses large-scale, Phase II global trials with its neuroinflammation pipeline for Parkinson’s and Alzheimer’s disease. Its CEO talks to Scrip about what's in store for the South Korean biotech.
Plus deals involving Takeda/OrigiMed, Amcure/Hinova, AUM/Newsoara, Taiho/Lung Therapeutics, 3D Medicines/Aravive, HitGen/Baiyunshan, Dong-A/Jiangsu Hengrui, and Crescita/Juyou.
As the prolonged COVID-19 pandemic continues to take a toll globally, South Korean pharma firms’ overseas drug development activities are increasingly being disrupted by the impact.